ONO 6126

Drug Profile

ONO 6126

Alternative Names: DE-103; ONO-6126

Latest Information Update: 25 Mar 2009

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Developer Santen Pharmaceutical
  • Class Anti-inflammatories; Antiasthmatics; Bronchodilators
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Allergic conjunctivitis; Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 23 May 2008 Phase-II clinical trials in Allergic conjunctivitis in Japan (Ophthalmic)
  • 30 Apr 2006 Discontinued - Phase-II for Chronic obstructive pulmonary disease in North America (PO)
  • 28 Mar 2006 Preclinical trials in Allergic conjunctivitis in Japan (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top